Navigation Links
Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference
Date:11/24/2014

SAN DIEGO, Nov. 24, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), at The New York Palace Hotel in New York.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is embracing the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena's internally discovered drug, BELVIQ® (lorcaserin HCl), is approved in the United States, and Arena is focused on discovering, developing and commercializing additional drugs to address unmet medical needs. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about embracing the challenge of improving health; seeking to bring innovative medicines to patients; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing, supply and marketing issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for (or Arena or a collaborator may not pursue) further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersCraig M. Audet, Ph.D., Senior Vice President,

David Schull, PresidentOperations & Head of Global Regulatory Affairs

david.schull@russopartnersllc.comcaudet@arenapharm.com

 858.717.2310858.453.7200, ext. 1612 www.arenapharm.com
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
2. Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
3. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
4. Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3
5. Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
6. Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting
7. Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension
10. Arena Solutions And SiliconExpert Partner To Reduce Supply Chain Risk
11. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2018)... ... September 14, 2018 , ... "As of Thursday, Sept. 13, 2018, ... Hurricane Florence. I am planning this Women of Influence tour with the knowledge that ... and knowing I have to hold onto my faith through this storm. So many ...
(Date:9/13/2018)... ... 13, 2018 , ... NCPDP announced today that its ... implementation of the NCPDP SCRIPT Standard Version 2017071 ahead of the January 1, ... by the industry as vital enhancements in improving patient safety, clinical decision-making, and ...
(Date:9/12/2018)... ... September 12, 2018 , ... Surgical Theater will be ... from September 19-22. The IT + Revenue Cycle Conference provides Surgical Theater with ... the use of Precision Virtual Reality™ medical visualization platform. This 360VR technology allows ...
Breaking Medicine Technology:
(Date:8/31/2018)... ... August 31, 2018 , ... Kessler Foundation, a ... of an MRI Simulator. In the MRI Simulator, the individual experiences the conditions ... this mock scan experience, research participants become accustomed to the sights and sounds ...
(Date:8/31/2018)... ... August 31, 2018 , ... Nitro Circus hosted the inaugural A Night ... an action sports gathering to celebrate the life of Erik Roner, world-renowned skier, skydiver ... Erik’s wife, Annika and their two small children, Oskar (8) and Kasper (4). A ...
(Date:8/31/2018)... AMES, Iowa (PRWEB) , ... August 31, 2018 , ... ... demonstration jump as part of the Iowa State Cyclones season opener game. At 7pm, ... game, right as the National Anthem starts to play, Team Fastrax™ will jump in ...
(Date:8/29/2018)... ... August 29, 2018 , ... Shady Grove Fertility (SGF), ... announced that they will be relocating two of their offices this September. Their ... just a few miles away, located on the campus of UPMC PinnacleHealth Fredericksen Outpatient ...
(Date:8/29/2018)... ... August 29, 2018 , ... The Vape Mall has ... to provide information on the similarities and differences between smoking and vaping. , ... more importantly, differences between vaping and smoking. To accurately inform consumers on both ...
Breaking Medicine News(10 mins):